USADA announced today that Mairbek Taisumov, of Vienna, Austria, has accepted a six-month sanction for a violation of the UFC® Anti-Doping Policy after testing positive for a prohibited substance.
Taisumov, 30, tested positive for stanozolol metabolites 3′-hydroxystanozolol-O-glucuronide and 16β-hydroxystanozolol-O-glucuronide as the result of an in-competition urine sample he provided on September 15, 2018 at UFC Fight Night in Moscow, Russia. Stanozolol is a non-Specified Substance in the class of Anabolic Agents and prohibited at all times under the UFC Anti-Doping Policy, which has adopted the World Anti-Doping Agency Prohibited List.
Following notification of his positive test, Taisumov provided USADA with information about dietary supplement products he was using before and at the time of the relevant sample collection. USADA obtained open packages of the dietary supplements and collaborated with the Russian Anti-Doping Agency (RUSADA) to source unopened packages from Russia. Although no prohibited substances were listed on the supplement labels, product analysis conducted on both the open and independently sourced, unopened packages of the products by the WADA-accredited laboratory in Salt Lake City, Utah, indicated that they all contained stanozolol.
The presence of an undisclosed prohibited substance in a product is regarded as contamination. Accordingly, the products have since been added to the list of high-risk supplements maintained on USADA’s online dietary supplement safety education and awareness resource – Supplement 411 (www.Supplement411.org).
Under the UFC Anti-Doping Policy, as well as the World Anti-Doping Code, the determination that an athlete’s positive test was caused by a contaminated product may result in a reduced sanction. Where contamination is established, the sanction for a doping offense involving a non-Specified Substance ranges from a reprimand and no period of ineligibility, at a minimum, to a two-year period of ineligibility, at a maximum.
Here, USADA took into consideration the circumstances that resulted in Taisumov’s positive test and determined that a six-month period of ineligibility was an appropriate sanction under the rules for his violation.
Taisumov’s six-month period of ineligibility began on October 8, 2018, the date his provisional suspension was imposed. Under the rules, any decision concerning competition results is handled by the UFC.
USADA conducts the year-round, independent anti-doping program for all UFC athletes. USADA is an independent, non-profit, non-governmental agency whose sole mission is to preserve the integrity of competition, inspire true sport, and protect the rights of clean athletes. In an effort to aid UFC athletes, as well as their support team members, in understanding the rules applicable to them, USADA provides comprehensive instruction on the UFC Anti-Doping Program website (https://UFC.USADA.org) regarding the testing process and prohibited substances, how to obtain permission to use a necessary medication, and the risks and dangers of taking supplements as well as performance-enhancing and recreational drugs. In addition, the agency manages a drug reference hotline, Drug Reference Online (https://UFC.GlobalDRO.com), conducts educational sessions, and proactively distributes a multitude of educational materials, such as the Prohibited List, easy-reference wallet cards, and periodic athlete alerts. Many of the resources available to athletes are provided in multiple languages, including Russian, Spanish, French, Portuguese, Korean, and Japanese.
Along with education and testing, robust anti-doping programs enable investigations stemming from tips and whistleblowers. USADA makes available a number of ways to report the abuse of performance-enhancing drugs in sport in an effort to protect clean athletes and promote clean competition. Any tip can be reported using the USADA Play Clean Tip Center, by email at firstname.lastname@example.org, by phone at 1 877-Play Clean (1-877-752-9253), or by mail.
For more information or media inquiries, email email@example.com.